SCHEMBL1788017

SCHEMBL1788017

Cn1nccc1C(=O)NCc1ccc2c(c1)CCN(C1=CC=C1)CC2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
TP53 P04637 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.47
KMT2A Q03164 1/20 0.47
PRMT5 O14744 2/20 0.44
WDR77 Q9BQA1 2/20 0.44
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
ACE2 Q9BYF1 1/20 0.38
GALR3 O60755 2/20 0.37
RAB9A P51151 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
IDO1 P14902 1/20 0.36
MAPK14 Q16539 1/20 0.36
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1788446 0.82 ACE2 (0.53) LMNATP53ACE2TSHRHTT
SCHEMBL1790517 0.81 LMNA (0.51) LMNATP53L3MBTL1KMT2AMAPK14
SCHEMBL1792348 0.80 CYP1A2 (0.51) LMNATP53RAB9ATSHR
SCHEMBL1788015 0.80 LMNA (0.55) LMNATP53L3MBTL1KMT2APRMT5
SCHEMBL1790155 0.80 POLB (0.45) LMNATP53KMT2AACE2RAB9A
SCHEMBL1787647 0.80 KMT2A (0.47) LMNATP53L3MBTL1KMT2AROCK2
SCHEMBL1789742 0.79 HPGD (0.51) L3MBTL1KMT2APRMT5WDR77RAB9A
SCHEMBL1788052 0.79 TP53 (0.44) LMNATP53KMT2ARAB9AMAPK14
SCHEMBL1787346 0.79 MAPK14 (0.41) LMNATP53IDO1MAPK14PRKAB2
SCHEMBL1790034 0.79 LMNA (0.41) LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 LMNA 2172/4885TP53 4800/4885L3MBTL1 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.